At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of the international phase 2 Borealis-1™ trial, which evaluated the efficacy and safety of gemcitabine and cisplatin plus apatorsen, a novel antisense oligonucleotide that inhibits Hsp27 production, in patients with advanced bladder cancer.
Allergy & Immunology
